Revised proposal from the Board's Nomination and Remuneration Committee to the Annual General Meeting of shareholders.
Dr. Ann Hanham has informed that she no longer is available for re-election to the Board of Directors of Biotie Therapies Corp. due to her recently emerged other commitments. The Nomination and Remuneration Committee now proposes that the number of members of the Board of Directors would be seven (7).
The Nomination and Remuneration Committee proposes that Peter Fellner, Bernd Kastler, Pauli Marttila, Riku Rautsola and Pierre Serrure would be re-elected as members of the Board of Directors and Merja Karhapää, Chief Legal Officer of Sanoma Corporation, and James S. Shannon, CEO of Cerimon Phamaceuticals, Inc., would be elected as new members of the Board of Directors for the term expiring at the end of the following annual general meeting. Ms. Karhapää and Dr. Shannon have given their consent regarding the appointment.
